| abstract |
The invention relates to novel interfuranylene-prosta-cyclin derivatives of the general formula (I) n<CHEM>n whereinn R<1> stands for hydrogen or a straight or branched chain C16 alkyl group, an inorganic cation or for the protonated form of a base containing an amino group;n R<2> stands for hydrogen, a C1-4 alkanoyl or benzoyl group, a monosubstituted benzoyl, trialkylsilyl or an alkoxy-alkyl group;n R<3> stands for a straight or branched chain C1-6 alkyl group, a phenyl group optionally substituted by halogen or by a C1-4 alkyl group, a heteroaryl group optionally substituted by halogen or by a C1-4 alkyl group or a cycloalkyl group;n A stands for an ethylene or for a cis- or trans-vinylene or -C IDENTICAL C- group;n B means a chemical bond, a -CHR<5>-, -CHR<5>-CH2- or a -CH2-O- group: andn R<6> means hydrogen or a C1-4 alkyl group. n<??>The compounds of the formula (I) can be used therapeutically as platelet aggregation inhibiting, anti-thrombotic, hypotensive and anti-antherosclerotic agents; they are much more stable than the natural prostacyclin derivatives. |